Rosaria Di Lorenzo1, Michela Cameli1, Marisa Bolondi1, Giulia Landi1, Valentina Moretti1, Chiara Piemonte1, Gabriella Pollutri1. 1. Dr. Di Lorenzo, MD, Psychiatrist, SPDC c/o NOCSAE, via P. Giardini, 1355, 41126 Baggiovara (Modena), Mental Health Department, Az-Usl, Modena, Italy. Dr. Cameli, MD, Psychiatrist, Private accredited psychiatric hospital, Villa Maria Luigia, via Montepelato Nord, 41, 43022 Monticelli Terme (PR), Italy. Drs. Bolondi, MD, Landi, MD, Piemonte, MD, Pollutri, MD, Residents in Psychiatry, University of Modena and Reggio Emilia, via del Pozzo, 71, 41224 Modena, Italy. Dr. Moretti, MD, Psychiatrist, Centro Salute Mentale, via Mandriolo Superiore, 11, 42015 Correggio, AzUsl Reggio Emilia, Italy.
Abstract
OBJECTIVES: To evaluate paliperidone palmitate (PP) effectiveness, safety and adherence to treatment. METHODS: We collected data of all patients (n = 50) affected by Schizophrenia Disorders, treated with PP for a 3 month minimum period in the outpatient setting of Mental Health Department in Modena, from 01/01/2014 to 31/01/2015. We evaluated reasons and modality for PP implementation, improvement in symptom and functioning scales, adverse effects, discontinuations and relapses. We statistically correlated socio-demographic and clinical variables of our sample with PP therapeutic variables. RESULTS: We registered an improvement in all scales, with a superior percentage in PANSS positive subscale. The mean PP dose in some patients was lower than official indications, although our sample was clinically severe. Illness relapses affected 60% and dropout 18% of patients. PP was well tolerated and in just a few cases adverse events required treatment interruption. The risk factors for discontinuation were represented by "lack of therapeutic compliance" (HR = 4.11, p < 0.0001) and "inefficacy" (HR = 1.67, p < 0.0001). CONCLUSIONS: With limitations of observational design, this research highlights that PP was well tolerated and effective in improving both psychotic symptoms and functioning, but moderately effective in preventing relapse, probably due to clinical severity of our patients associated with extremely cautious and flexible PP prescriptions.
OBJECTIVES: To evaluate paliperidone palmitate (PP) effectiveness, safety and adherence to treatment. METHODS: We collected data of all patients (n = 50) affected by Schizophrenia Disorders, treated with PP for a 3 month minimum period in the outpatient setting of Mental Health Department in Modena, from 01/01/2014 to 31/01/2015. We evaluated reasons and modality for PP implementation, improvement in symptom and functioning scales, adverse effects, discontinuations and relapses. We statistically correlated socio-demographic and clinical variables of our sample with PP therapeutic variables. RESULTS: We registered an improvement in all scales, with a superior percentage in PANSS positive subscale. The mean PP dose in some patients was lower than official indications, although our sample was clinically severe. Illness relapses affected 60% and dropout 18% of patients. PP was well tolerated and in just a few cases adverse events required treatment interruption. The risk factors for discontinuation were represented by "lack of therapeutic compliance" (HR = 4.11, p < 0.0001) and "inefficacy" (HR = 1.67, p < 0.0001). CONCLUSIONS: With limitations of observational design, this research highlights that PP was well tolerated and effective in improving both psychotic symptoms and functioning, but moderately effective in preventing relapse, probably due to clinical severity of our patients associated with extremely cautious and flexible PP prescriptions.
Entities:
Keywords:
effectiveness and safety; outpatient care setting; paliperidone palmitate treatment; relapse and adverse effects
Authors: Srihari Gopal; David W Hough; Haiyan Xu; Julia M Lull; Cristiana Gassmann-Mayer; Bart M Remmerie; Marielle H Eerdekens; David W Brown Journal: Int Clin Psychopharmacol Date: 2010-09 Impact factor: 1.659
Authors: A Schreiner; P Bergmans; P Cherubin; S Keim; P-M Llorca; B Cosar; A Petralia; G Corrivetti; L Hargarter Journal: J Psychopharmacol Date: 2015-05-21 Impact factor: 4.153